Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury

Pharmacology

Volumn 94, Issue 3-4, 2014, Pages 190-197

  Adachi, Eri ^a   Hirose Sugiura, Tomoko ^a   Kato, Yukio ^a   Ikebuchi, Fumie ^a   Yamashita, Atsuko ^a   Abe, Tetsushi ^b   Fukuta, Kazuhiro ^b   Adachi, Kiichi ^b   Matsumoto, Kunio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Saito Laboratory   (Japan)

Author keywords

Acute kidney injury; Growth factor; Met; Plasma clearance

Indexed keywords

GLYCEROL; RECOMBINANT SCATTER FACTOR; HGF PROTEIN, HUMAN; RECOMBINANT PROTEIN; SCATTER FACTOR;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; KIDNEY ISCHEMIA; MALE; NEPHRECTOMY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; UREA NITROGEN BLOOD LEVEL; VOLUME OF DISTRIBUTION; ACUTE KIDNEY INJURY; ANIMAL; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; BLOOD UREA NITROGEN; GLYCEROL; HEPATOCYTE GROWTH FACTOR; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; NEPHRECTOMY; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REPERFUSION INJURY;

EID: 84910091858     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000363412     Document Type: Article

References (30)

1. Nakamura T, Sakai K, Nakamura T, Matsumoto K: Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011; 26: 188-202.
2. Trusolino L, Bertotti A, Comoglio PM: MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-848.
3. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
4. Liu Y: Hepatocyte growth factor in kidney fibrosis: Therapeutic potential and mechanisms of action. Am J Physiol 2004; 287:F7-F16.
5. Kjelsberg C, Sakurai H, Spokes K, Birchmeier C, Drummond I, Nigam S, Cantley LG: Met-/-kidneys express epithelial cells that chemotax and form tubules in response to EGF receptor ligands. Am J Physiol 1997; 272: F222-F228.
6. Ishibe S, Karihaloo A, Ma H, Zhang J, Marlier A, Mitobe M, Togawa A, Schmitt R, Czyczk J, Kashgarian M, Geller DS, Thorgeirsson SS, Cantley LG: Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 2009; 136: 337-345.
7. Ma H, Saenko M, Opuko A, Togawa A, Soda K, Marlier A, Moeckel GW, Cantley LG, Ishibe S: Deletion of the Met receptor in the collecting duct decreases renal repair following ureteral obstruction. Kidney Int 2009; 76: 868-876.
8. Dai C, Saleem MA, Holzman LB, Mathieson P, Liu Y: Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int 2010; 77: 962-973.
9. Zhou D, Tan RJ, Lin L, Zhou L, Liu Y: Activation of hepatocyte growth factor receptor, cmet, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int 2013; 84: 509-520.
10. Ido A, Moriuchi A, Numata M, Murayama T, Teramukai S, Marusawa H, Yamaji N, Setoyama H, Kim ID, Chiba T, Higuchi S, Yokobe M, Fukushima M, Shimizu A, Tsubouchi H: Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: A phase I/II clinical trial, following preclinical studies to ensure safety. J Transl Med 2011; 9: 55-66.
11. Kawaida K, Matsumoto K, Shimazu H, Nakamura T: Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A 1994; 91: 4357-4361.
12. Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y: Importance of the liver in plasma clearance of hepatocyte growth factors in rats. Am J Physiol 1992; 263:G642-G649.
13. Zioncheck TF, Richardson L, DeGuzman GG, Modi NB, Hansen SE, Godowski PJ: The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. Endocrinology 1994; 134: 1879-1887.
14. Uematsu Y, Fujise N, Kohsaka K, Masunaga H, Higashio K: Effective administration route for the deleted form of hepatocyte growth factor to exert its pharmacological effects. J Pharm Sci 1999; 88: 131-135.
15. Liu KX, Kato Y, Yamazaki M, Higuchi O, Nakamura T, Sugiyama Y: Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats. Hepatology 1993; 17: 651-660.
16. Fukuta K, Adachi E, Matsumoto K, Nakamura T: Different reactivities of enzyme-linked immunosorbent assays for hepatocyte growth factor. Clin Chim Acta 2009; 402: 42-49.
17. Food and Drug Administration: Guidance of industry. Bioanalytical method validation. Washington, Food and Drug Administration, May 2001.
18. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R: Workshop/conference report quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J 2007; 9:E30-E42.
19. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273: 4135-4142.
20. Ichimura T, Brooks CR, Bonventre JV: Kim- 1/Tim-1 and immune cells: Shifting sands. Kidney Int 2012; 81: 809-811.
21. Igawa T, Kanda S, Kanetake H, Saitoh Y, Ichihara A, Tomita Y, Nakamura T: Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun 1991; 174: 831-838.
22. Montesano R, Matsumoto K, Nakamura T, Orci L: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901-908.
23. Liu Y, Sun AM, Dworkin LD: Hepatocyte growth factor protects renal epithelial cells from apoptotic cell death. Biochem Biophys Res Commun 1998; 246: 821-826.
24. Fornoni A, Li H, Foschi A, Striker GE, Striker LJ: Hepatocyte growth factor, but not insulinlike growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am J Pathol 2001; 158: 275-280.
25. Tajima H, Matsumoto K, Nakamura T: Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res 1992; 202: 423-431.
26. Tajima H, Higuchi O, Mizuno K, Nakamura T: Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regeneration organ after injury. J Biochem 1992; 111: 401-406.
27. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT: Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994; 269: 11216-11223.
28. Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, Gallagher JT: Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J Biol Chem 1998; 273: 271-278.
29. Sugiura T, Takahashi S, Sano K, Abe T, Fukuta K, Adachi K, Nakamura T, Matsumoto K, Nakamichi N, Kato Y: Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans. J Pharm Sci 2013; 102: 237-249.
30. Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y: Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. Am J Physiol 1998; 275: E835-E842.